FibroBiologics, Inc. — 2023 Form 10-K Summary
Business context and reporting period
FibroBiologics is a clinical-stage cell therapy company developing fibroblast-based treatments for chronic diseases. This annual report covers the year ended December 31, 2023; the company’s direct listing and Nasdaq trading began January 31, 2024. It had no approved products and generated no product revenue.
Lead programs include CybroCell for degenerative disc disease, which has FDA IND clearance for a U.S. Phase 1/2 study conditional on master cell bank approval, and CYMS101 for multiple sclerosis, for which a five-person Phase 1 study was completed in Mexico. CYWC628 for wound healing remains preclinical; other research includes thymic and splenic involution, psoriasis and certain cancers.
Key financial metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $2.368 million | $1.147 million |
| General, administrative and other expense | $6.521 million | $3.320 million |
| Total operating expenses / operating loss | $8.889 million | $4.467 million |
| Net loss | $16.485 million | $5.121 million |
| Net loss attributable to common stockholders; reported loss per share | $19.058 million; $(0.68) | $5.121 million; $(0.18) |
| Net cash used in operating activities | $6.401 million | $4.066 million |
| Net cash used in investing activities | $0.495 million | None |
| Net cash provided by financing activities | $13.793 million | $5.925 million |
At December 31, 2023, cash and cash equivalents were $9.163 million, total assets $11.821 million, current liabilities $9.183 million, and total liabilities $10.568 million. The balance sheet showed a $7.236 million liability instrument and $1.747 million of operating lease liabilities. Convertible notes had been converted, leaving no outstanding debt at year-end. The company reported a $1.253 million stockholders’ equity balance. No meaningful revenue-based margin comparison is available because the company had no revenue.
Material changes versus 2022
- Net loss increased by $11.364 million; operating expenses nearly doubled, reflecting higher R&D staffing and activity, stock-based compensation, and public-company preparation costs.
- The 2023 loss included a $7.236 million noncash fair-value charge on a liability instrument related to the share purchase agreement, plus $0.213 million of other loss. The $19.058 million loss attributable to common stockholders also included a $2.573 million deemed dividend under the ROFN arrangement.
- Operating cash use rose by $2.335 million. Financing included $14.945 million net proceeds from Series B preferred stock and $1.193 million from Series B-1 preferred stock; cash outflows included $2.645 million paid to FibroGenesis under the ROFN Agreement.
- The 2022 convertible notes were converted into Series B preferred shares during 2023. The company also invested $0.495 million in property and equipment.
Outlook, risks and unusual items
Management expects significant losses and operating cash outflows to continue and says existing capital, including approximately $1.924 million raised through the share purchase facility in February 2024, is expected to fund the current operating plan through at least February 28, 2025. This estimate depends on assumptions that could prove incorrect. The filing provides no revenue or earnings guidance.
Near-term planned work includes cell-bank development and transfer to a CDMO, preparation for clinical studies, a possible CYWC628 IND submission as early as 2024, and further CYMS101 and CYTER915 preclinical work. Management’s listed program estimates are preliminary and subject to change. The company relies on external CROs and CDMOs and must resolve manufacturing and regulatory requirements before advancing key trials.
- Funding and dilution: Further capital will be required. The share purchase agreement provides potential access to up to $100 million over five years, subject to drawdown conditions and trading volume, but entails a 2% commitment fee and warrants; access to the full amount is not assured and use may dilute shareholders.
- Development and manufacturing: Clinical success, regulatory approval, scale-up, cell-bank transfer and consistent cell-product manufacturing are uncertain. No product candidate is approved for sale.
- Controls: Management identified a material weakness in internal control over financial reporting due to insufficient segregation of duties and concluded disclosure controls and procedures were not effective as of year-end. The auditor did not express an opinion on control effectiveness.
- Governance and ownership: The CEO holds 2,500 Series C preferred shares with 13,000 votes each; the filing reports approximately 60% of total voting power for him. The company is a controlled company.
- Other: The company reported no material legal proceedings. It disclosed that cash balances can exceed the $250,000 federally insured limit and that it lacks environmental liability insurance.
Most important facts for investors to verify
- Reconcile the filing’s inconsistent accumulated-deficit references: audited statements report $24.357 million at December 31, 2023, while portions of the narrative cite approximately $17.1 million.
- Confirm the February 2024 share purchase facility proceeds: the notes state $1.924 million, while the subsequent-events disclosure states $1.921 million.
- Track cash runway, burn rate and financing needs, including the share purchase facility’s fees, warrant terms, drawdown limitations and potential dilution.
- Monitor FDA requirements and timing for CybroCell, CYMS101 and CYWC628, as well as CDMO cell-bank transfer and manufacturing readiness.
- Assess remediation of the material weakness and the implications of Series C super-voting rights for common-stock holders.